- Home
- ANSS vs BIIB Comparison
ANSS vs BIIB Comparison
Compare ANSS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSS
- BIIB
- Stock Information
- Founded
- ANSS 1970
- BIIB 1978
- Country
- ANSS United States
- BIIB United States
- Employees
- ANSS N/A
- BIIB N/A
- Industry
- ANSS Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ANSS Technology
- BIIB Health Care
- Exchange
- ANSS Nasdaq
- BIIB Nasdaq
- Market Cap
- ANSS 29.4B
- BIIB 18.8B
- IPO Year
- ANSS 1996
- BIIB 1991
- Fundamental
- Price
- ANSS $353.21
- BIIB $133.19
- Analyst Decision
- ANSS Buy
- BIIB Buy
- Analyst Count
- ANSS 2
- BIIB 27
- Target Price
- ANSS $352.50
- BIIB $188.17
- AVG Volume (30 Days)
- ANSS 578.9K
- BIIB 1.3M
- Earning Date
- ANSS 07-30-2025
- BIIB 07-31-2025
- Dividend Yield
- ANSS N/A
- BIIB N/A
- EPS Growth
- ANSS 35.35
- BIIB 26.39
- EPS
- ANSS 6.74
- BIIB 10.12
- Revenue
- ANSS $2,583,095,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- ANSS $11.48
- BIIB N/A
- Revenue Next Year
- ANSS $10.05
- BIIB N/A
- P/E Ratio
- ANSS $52.43
- BIIB $13.16
- Revenue Growth
- ANSS 15.98
- BIIB 1.59
- 52 Week Low
- ANSS $275.06
- BIIB $110.04
- 52 Week High
- ANSS $363.03
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- ANSS 68.04
- BIIB 60.40
- Support Level
- ANSS $330.11
- BIIB $123.90
- Resistance Level
- ANSS $340.61
- BIIB $134.75
- Average True Range (ATR)
- ANSS 5.33
- BIIB 3.53
- MACD
- ANSS 1.26
- BIIB 0.04
- Stochastic Oscillator
- ANSS 91.85
- BIIB 86.48
About ANSS ANSYS Inc.
Ansys is an engineering software company that provides simulation capabilities for structural, fluids, semiconductor power, embedded software, optical, and electromagnetic properties. Ansys employs over 4,000 people and serves over 50,000 customers globally.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.